WO2018229551A3 - Methods to treat opioid use disorder - Google Patents

Methods to treat opioid use disorder Download PDF

Info

Publication number
WO2018229551A3
WO2018229551A3 PCT/IB2018/000770 IB2018000770W WO2018229551A3 WO 2018229551 A3 WO2018229551 A3 WO 2018229551A3 IB 2018000770 W IB2018000770 W IB 2018000770W WO 2018229551 A3 WO2018229551 A3 WO 2018229551A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
use disorder
opioid use
treat opioid
treat
Prior art date
Application number
PCT/IB2018/000770
Other languages
French (fr)
Other versions
WO2018229551A2 (en
Inventor
Celine M. LAFFONT
Malcolm A. YOUNG
Norma L. FOX
Barbara R. HAIGHT
Susan M. LEARNED
Original Assignee
Indivior Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indivior Uk Limited filed Critical Indivior Uk Limited
Priority to NZ760033A priority Critical patent/NZ760033A/en
Priority to AU2018283724A priority patent/AU2018283724B2/en
Priority to EP18762131.3A priority patent/EP3638240A2/en
Publication of WO2018229551A2 publication Critical patent/WO2018229551A2/en
Publication of WO2018229551A3 publication Critical patent/WO2018229551A3/en
Priority to IL271430A priority patent/IL271430A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The disclosure provides sustained-release buprenorphine formulations that produce therapeutic plasma concentration levels of buprenorphine in patients to treat opioid use disorder.
PCT/IB2018/000770 2017-06-16 2018-06-15 Methods to treat opioid use disorder WO2018229551A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
NZ760033A NZ760033A (en) 2017-06-16 2018-06-15 Methods to treat opioid use disorder
AU2018283724A AU2018283724B2 (en) 2017-06-16 2018-06-15 Methods to treat opioid use disorder
EP18762131.3A EP3638240A2 (en) 2017-06-16 2018-06-15 Methods to treat opioid use disorder
IL271430A IL271430A (en) 2017-06-16 2019-12-15 Methods to treat opioid use disorder

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US201762521121P 2017-06-16 2017-06-16
US62/521,121 2017-06-16
US201762572331P 2017-10-13 2017-10-13
US62/572,331 2017-10-13
US201762572996P 2017-10-16 2017-10-16
US62/572,996 2017-10-16
US201762598338P 2017-12-13 2017-12-13
US62/598,338 2017-12-13
US201862632995P 2018-02-20 2018-02-20
US62/632,995 2018-02-20
US201862656216P 2018-04-11 2018-04-11
US62/656,216 2018-04-11
US201862680935P 2018-06-05 2018-06-05
US62/680,935 2018-06-05

Publications (2)

Publication Number Publication Date
WO2018229551A2 WO2018229551A2 (en) 2018-12-20
WO2018229551A3 true WO2018229551A3 (en) 2019-02-14

Family

ID=63407480

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2018/000770 WO2018229551A2 (en) 2017-06-16 2018-06-15 Methods to treat opioid use disorder

Country Status (5)

Country Link
EP (1) EP3638240A2 (en)
AU (1) AU2018283724B2 (en)
IL (1) IL271430A (en)
NZ (1) NZ760033A (en)
WO (1) WO2018229551A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11000520B2 (en) 2014-11-07 2021-05-11 Indivior Uk Limited Buprenorphine dosing regimens

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016071767A1 (en) * 2014-11-07 2016-05-12 Indivior Uk Limited Buprenorphine dosing regimens

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2309766T3 (en) 2004-06-04 2008-12-16 Camurus Ab SLOW RELEASE LIQUID FORMULATIONS.
EP1843751B1 (en) 2005-01-21 2020-09-30 Camurus Ab Pharmaceutical lipid compositions
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2513267B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
US8975270B2 (en) 2010-06-08 2015-03-10 Rb Pharmaceuticals Limited Injectable flowable composition comprising buprenorphine
WO2017077389A1 (en) 2015-11-04 2017-05-11 Indivior Uk Limited Quantification of drugs in biological samples

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016071767A1 (en) * 2014-11-07 2016-05-12 Indivior Uk Limited Buprenorphine dosing regimens

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANON: "FDA Approves SUBLOCADE(TM) (Buprenorphine Extended-Release), the First and Only Once-Monthly Injectable Buprenorphine Formulation to Treat Moderate to Severe Opioid Use Disorder", 30 November 2017 (2017-11-30), XP055528322, Retrieved from the Internet <URL:https://web.archive.org/web/20171204174528/https://www.multivu.com/players/English/8221151-indivior-sublocade-buprenorphine-fda-approval/> [retrieved on 20181129] *
ANON: "HIGHLIGHTS OF PRESCRIBINGINFORMATION SUBLOCADE", 1 November 2017 (2017-11-01), XP055528072, Retrieved from the Internet <URL:http://indivior.com/wp-content/uploads/2017/11/SUBLOCADE-Prescribing-Information.pdf> [retrieved on 20181128] *
RICHARD C CRIST ET AL: "An Intronic Variant in OPRD1 Predicts Treatment Outcome for Opioid Dependence in African-Americans", NEUROPSYCHOPHARMACOLOGY., vol. 38, no. 10, 23 April 2013 (2013-04-23), US, pages 2003 - 2010, XP055528570, ISSN: 0893-133X, DOI: 10.1038/npp.2013.99 *

Also Published As

Publication number Publication date
AU2018283724B2 (en) 2021-08-19
NZ760033A (en) 2023-02-24
AU2018283724A2 (en) 2020-01-23
IL271430A (en) 2020-01-30
EP3638240A2 (en) 2020-04-22
WO2018229551A2 (en) 2018-12-20
AU2018283724A1 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
ZA202004100B (en) Diaryl macrocycles as modulators of protein kinases
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2018008426A (en) Anti-egfr combinations for treating tumors.
MY187540A (en) Compounds active towards bromodomains
MX2021006734A (en) Method for treating cancer.
PH12015502161A1 (en) Therapeutic compounds and compositions
MX2018008427A (en) Anti-cd20 combinations for treating tumors.
GEP20217317B (en) Combination therapy for the treatment of cancer
EA201791736A1 (en) COMBINED THERAPY FOR CANCER TREATMENT
MX2018005544A (en) Use of tlr8 agonists to treat cancer.
PH12018501443A1 (en) Methods of administering hepcidin
MX2020001727A (en) Combination therapy.
MX2017006437A (en) Spiro-isoquinoline-1,4&#39;-piperidine compounds having multimodal activity against pain.
MX2018005233A (en) Combination of bcl-2 inhibitor and mek inhibitor for the treatment of cancer.
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
EP4353320A3 (en) Blood plasma and plasma fractions as therapy for tumor growth and progression
MX2019008233A (en) Targeted doxorubicin-gold nanoconjugates for tumor therapy.
MX2017014456A (en) Therapeutic uses of l-4-chlorokynurenine.
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
PH12016501838A1 (en) Compounds and their methods of use
EP3991749A3 (en) A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody
MX2019004804A (en) Treatment of prurigo nodularis.
MX2018010223A (en) Combination therapy for treatment of ovarian cancer.
MX2017016346A (en) Methods of treatment with taselisib.
WO2018229551A3 (en) Methods to treat opioid use disorder

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18762131

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018283724

Country of ref document: AU

Date of ref document: 20180615

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2018762131

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2018762131

Country of ref document: EP

Effective date: 20200116